Apollomics is a biopharmaceutical company discovering and developing mono- and combination- oncology therapies to harness the immune system.
Apollomics has raised $2.0M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in March 2026.
Apollomics's investors include K2VC, OrbiMed, Pan-Lin Capital, Ping An Capital, CMB International Capital Corporation.
Apollomics is headquartered in Foster City, United States.
Apollomics is a biopharmaceutical company discovering and developing mono- and combination- oncology therapies to harness the immune system.
Apollomics is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Apollomics — Funding & Investors." VCBacked, March 30, 2026, https://www.vcbacked.co/company/apollomics. Accessed July 28, 2026.
VCBacked. (2026). Apollomics — Funding & Investors. Retrieved July 28, 2026, from https://www.vcbacked.co/company/apollomics
{{cite web |title=Apollomics — Funding & Investors |url=https://www.vcbacked.co/company/apollomics |website=VCBacked |access-date=July 28, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated